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Aims The COVID-19 pandemic has led to a decline in hospitalizations for non-COVID-19-related conditions. We ex-




An administrative database covering hospital activity for England, the Health Episodes Statistics, was used to assess
a total of 286 697 hospitalizations for cardiac operations and interventions, as well as 227 257 hospitalizations for
myocardial infarction (MI) and 453 799 for heart failure (HF) from 7 January 2019 to 26 July 2020. Over the
3 months of ‘lockdown’, total numbers and mean reductions in weekly rates [n (%)], compared with the same
time period in 2019, were: coronary artery bypass grafting [2507 (64%)]; percutaneous coronary intervention
[5245 (28%)]; surgical [1324 (41%)] and transcatheter [284 (21%)] aortic valve replacement; mitral valve
replacement; implantation of pacemakers [6450 (44%)], cardiac resynchronization therapy with [356 (42%)]
or without [491 (46%)] defibrillation devices, and implantable cardioverter-defibrillators [501 (45%)]; atrial
fibrillation ablation [1902 (83%)], and other ablations [1712 (64%)] (all P < 0.001). Over this period, there
were 21 038 fewer procedures than in the reference period in 2019 (P < 0.001). These changes paralleled reduc-
tions in hospitalizations for MI [10 794 (27%)] and HF [63 058 (28%)] (both P < 0.001).
...................................................................................................................................................................................................
Conclusions The COVID-19 pandemic has led to substantial reductions in the number of cardiac operations and interventions
undertaken. An alternative strategy for healthcare delivery to patients with cardiac conditions during the COVID-
19 pandemic is urgently needed.
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Introduction
In the week commencing the 27 January 2020, the first two cases of
COVID-19 were diagnosed in England.1 On 11 March 2020, the
World Health Organization declared the COVID-19 pandemic.
Following a national ‘lockdown’ announcement on 23 March 2020,
hospitalizations for COVID-19 rose to a peak of 3099 on 1 April
2020. In order to meet unprecedented demands, hospitals
responded by increasing capacity for COVID-19 patients.2 It is appar-
ent that at least some hospital capacity for COVID-19 was made
available by reducing healthcare provision for patients non-COVID-
19 conditions.
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Cardiovascular disease is major cause of mortality and morbidity
worldwide and has been identified as a risk factor for total mortality
in COVID-19 patients.3,4 Yet, increasing evidence shows that during
the pandemic, patients with cardiac conditions were less likely to at-
tend hospital,5–7 perhaps because of confinement guidelines and/or
the perceived risk of contagion. In the ‘first wave’ of the COVID-19
pandemic, reports from the UK,8–10 Italy,5 Austria,11 China,12 and the
USA13,14 have shown substantial reductions in cardiac interventions.
The objective of the present study was to quantify nationwide
changes in the delivery of cardiac operations and interventions in
England during the ‘first wave’ of the COVID-19 pandemic.
Methods
This is a retrospective study of hospitalizations for cardiac conditions,
operations, and interventions from 7 January 2019 to 26 July 2020, which
encompasses the first ‘wave’ of the COVID-19 pandemic. We used the
National Health Service Hospital Episode Statistics (HES). These are
available to University Hospitals Birmingham under a data-sharing agree-
ment (section 251 of the National Health Service Act 2006), which obvi-
ates the need for Ethics Committee approval. The study was approved
by the Clinical Audit Department at the University Hospitals Birmingham,
Queen Elizabeth, and conforms to the Declaration of Helsinki.
Data collection
The HES database, provided by National Health Service Digital, contains
data on hospitalizations to all NHS hospitals in England (56.3 M popula-
tion in 2019). Wales and Scotland are not covered by HES. The main fo-
cus in this study was hospitalization for cardiac operations and
interventions, rather than on patient-level data. Episodes of care for the
different diagnoses, cardiac operations, and interventions were identified
using International Classification of Diseases 10th revision (ICD-10)
codes and the Office of Population, Censuses and Surveys Classification
of Interventions and Procedures version 4. The diagnosis, cardiac opera-
tion, or intervention was identified using ‘position 1’ of the hospitalization
coding (Supplementary material online, Table S1). The diagnoses included
myocardial infarction (MI) or heart failure (HF), whether or not patients
underwent an operation or an intervention. Operations and procedures
included coronary artery bypass graft (CABG), percutaneous coronary
intervention (PCI), surgical aortic valve replacement, mitral valve replace-
ment, transcathether aortic valve implantation, pacemaker implantation,
cardiac resynchronization-pacing device implantation, cardiac
resynchronization-defibrillation device implantation, implantable
cardioverter-defibrillator implantation, ablation for atrial fibrillation, and
ablation for conditions other than atrial fibrillation.
Statistical analysis
In analyses of hospitalization numbers, the total number of diagnoses, car-
diac operations, and interventions were quantified on a weekly basis.
Relative changes in hospitalizations were expressed as the difference in
weekly rates during the 3 months after the announcement of the national
lockdown (from week beginning on 23 March to week ending 21 June
2020) and the reference period in 2019 (from week beginning on 25
March to week ending on 23 June 2019). The total number of hospitaliza-
tions for clinical conditions, cardiac operations, and interventions in these
periods was also quantified. Continuous variables are expressed as mean
± 95% confidence intervals (95% CI). Normality was tested using the
Shapiro–Wilk test. Student’s t-tests were used to analyse differences be-
tween these time periods. Statistical analyses were undertaken using
Stata15 (StataCorp, TX, USA).
Results
Cardiac operations and interventions
Data from all 147 NHS hospitals were available from HES. From 7
January 2019 to 26 July 2020, there were 295 640 hospitalizations for
cardiac operations and interventions. Weekly rates of cardiac opera-
tions and interventions during the reference period in 2019 for all
cardiac operations and interventions, as well as for hospitalizations
for MI and HF were similar to the weekly rates over the year 2019
(data not shown).
The decline in hospitalizations for cardiac operations and interven-
tions began on the week of 2 March 2020,2 weeks before the lock-
down was announced. The most marked reductions in average
weekly rates occurred during April 2020: atrial fibrillation ablation
(97%), other ablations (91%), and mitral valve replacements
(90%) (Figure 1). In the week of 13 April 2020, a gradual increase
was observed for all operations and interventions. By the week of 20
July 2020, weekly rates remained below 2019 levels for most opera-
tions and interventions.
From 7 January 2019 to 26 July 2020, there were 295 640 cardiac
operations or interventions. Over the 3 months of lockdown, there
was a reduction in hospitalizations for cardiac operations and inter-
ventions from 50 508 during the reference period in 2019 to 29 470
(Table 1). In addition, there were 6450 fewer pacemaker implanta-
tions, 5245 fewer PCIs, and 2507 fewer CABGs (Table 1). In terms of
per cent change in numbers, the most marked reductions were ob-
served for atrial fibrillation ablation [83% (95% CI 82–83)], other
ablations [64% (95% CI 63–64)], and CABG [64% (95% CI 63–64)]
(Figure 2). All comparisons of numbers of cardiac operations and
interventions over the 3 months of lockdown with the numbers in
the reference period in 2019 were statistically significant (P < 0001).
As shown in Figure 3, significant reductions (all P < 0.001) in both
emergency and elective hospitalizations were observed for most car-
diac operations and interventions in relation to the reference period
in 2019. In the case of emergency ablation for conditions other than
atrial fibrillation, an overall reduction was also observed (Figure 3),
but the weekly rate was highly variable (median change: 7.14%;
interquartile range31.6 to 16.7).
What’s new?
• The first wave of the COVID-19 pandemic led to a dramatic,
nationwide reduction in the delivery of cardiac operations and
interventions, as well as in the number of hospitalizations for
myocardial infarction and heart failure.
• The most marked reductions in cardiological practice were
observed for cardiac ablation and cardiac implantable
electronic device implantation.
• An alternative strategy for delivering healthcare to patients
with cardiac conditions during the COVID-19 pandemic is
urgently needed.
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Myocardial infarction and heart failure
As in the case of cardiac operations and interventions, the decline in
hospitalizations for MI and HF also began on the week of 2 March
2020, 2 weeks before announcement of the lockdown (Figure 4).
The greatest reduction in weekly rates for MI and HF hospitalizations
were observed on the week of 6 April 2020 (45% and 42%, respec-
tively). Weekly rates began to return towards 2019 levels by the
week of 13 April 2020 for MI and 20 April for HF. By the week of 20
July, weekly rates remained below 2019 levels for both MI (27%) and
HF (33%).
From 7 January 2019 to 26 July 2020, there were 227 257 hospital-
izations for MI and 453 799 for HF. Over the 3 months of lockdown,
there was a reduction in hospitalizations for MI from 50 508 during
the reference period in 2019 to 39 473. Similarly, there was a reduc-
tion in hospitalizations for HF from 224 650 in the 3-month reference
period in 2019 to 161 592 during the 3 months of lockdown
(Table 1). In terms of per cent change, hospitalizations decreased by
27% (95% CI 27–27) for MI and by 28% (95% CI 28–28) for HF.
Changes in the total number of hospitalizations for MI and HF were
statistically significant (P < 0001). Changes in weekly rates during the
3 months of lockdown in relation the reference period in 2019 were
also statistically significant (P < 0.001).
Discussion
This study explores the nationwide impact of the COVID-19 pan-
demic on the delivery of cardiac operations and interventions. The
main finding was a dramatic reduction in the number of cardiac oper-
ations and interventions undertaken during the ‘first wave’. Over the
3 months of lockdown, there were 63% fewer operations and inter-
ventions than in the same period in 2019. These changes occurred in
parallel with nearly 11 000 fewer hospitalizations for MI and over
63 000 fewer hospitalizations for HF. These findings are consistent
with those of Mohamed et al.,8 who also used HES data. The present
study adds further data on the nature of the hospitalization (emer-
gency or elective), hospitalizations for MI and HF, as well as the types
of cardiac ablation procedure and cardiac devices.
Rates of cardiac operations and interventions began to fall in ad-
vance of the announcement of the lockdown, mirroring the situation
reported in the USA.15 The inflexion point of the weekly rate curve
occurred in the 2nd week of March. These changes are likely to re-
flect increasing public awareness of the COVID-19, most likely trig-
gered by reports of severe acute respiratory syndrome coronavirus
2 in China and Northern Italy. In addition, an NHS declaration of a
Level 4 national incident in England on 30 January 2020,2 prepared
hospitals for the pandemic. The lowest weekly rates of cardiac opera-
tions and interventions occurred in April 2020. Cardiac ablation for
atrial fibrillation was the worst hit, followed by other ablations, mitral
valve replacements, and coronary artery bypass surgery. For most
operations and interventions, a gradual recovery was observed after
13 April. By late July 2020, none had returned to levels observed in
the reference period in 2019. Over the 3 months of lockdown, there
were 21 038 fewer operations or interventions, compared to the
same period in 2019 (Figure 5).
....................................................................................................................................................................................................................








Per cent reduction in
weekly rate (95% CI)
Cardiac conditions
Myocardial infarction 39 473 28 679 10 794 27 (27–27)
Heart failure 224 650 161 592 63 058 28 (28–28)
Total 264 123 190 271 73 852
Cardiac operations
CABG 3961 1454 2507 64 (63–64)
Aortic valve replacement 3240 1916 1324 41 (41–42)
Mitral valve replacement 438 172 266 58 (55–60)
Total 7639 3542 4097
Cardiac interventions
PCI 18 815 13 570 5245 28 (28–28)
TAVI 1373 1089 284 20 (19–22)
Pacemakers 14 662 8212 6450 44 (44–44)
CRT-pacing 1067 576 491 46 (45–47)
CRT-defibrillation 846 490 356 42 (41–43)
ICD 1110 609 501 45 (44–46)
AF ablation 2316 414 1902 83 (82–83)
Other ablation 2680 968 1712 64 (63–64)
Total 42 869 25 928 16 941
aCompared to the reference period in 2019, all changes compared with the numbers in the reference period in 2019 were statistically significant (P < 0001).
AF, atrial fibrillation; CABG, coronary artery bypass graft; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; PCI, percutaneous coronary in-
tervention; TAVI, transcatheter aortic valve implantation.
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Figure 1 Number of cardiac operations and interventions in hospitalizations undertaken in England during the COVID-19 pandemic. Dashed hori-
zontal lines indicate the mean weekly rate of procedures during the reference period in 2019. Mean and 95% CI are shown above the lines. The black,
vertical, dashed line marks the announcement of the national ‘lockdown’ on 23 March 2020. AF, atrial fibrillation; AVR, surgical aortic valve replace-
ment; CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy-defibrillation; CRT-P, cardiac resynchronization therapy-pacing;
ICD, implantable cardioverter-defibrillator; MVR, mitral valve replacement; PCI, percutaneous coronary intervention; PPM, permanent pacemaker;
TAVI, transcatheter aortic valve implantation.
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We found substantial reductions in hospitalizations for MI and HF.
This is consistent with data from the USA showing that during the
early phase of the pandemic, cardiac catheterization laboratory acti-
vation for ST-segment elevation MI decreased by 38%.13 Braiteh
et al.14 also reported a drop of 41% in admissions for acute coronary
syndromes in New York State. In a nationwide survey in Italy
reported a 47% reduction in HF hospitalizations during the pan-
demic.7 Similar reports emerged from China.12 As to the causes for
the reductions in hospitalizations for MI and HF, a change in the inci-
dence of cardiac disease during the COVID-19 pandemic is an un-
likely explanation. More likely is that fewer patients attended
hospital, perhaps because of fear of contagion.
As well as a decline in emergency patient attendances as a
cause of reduction in cardiac operations and interventions, we
should also consider reductions in elective hospital capacity. In
this respect, most hospitals redeployed cardiac surgeons and car-
diologists away from their specialties to deal with COVID-19
patients. Hospital beds, intensive care unit beds as well as operat-
ing theatre and cardiac catheterization laboratory capacity were
also re-directed to deal with COVID-19 patients.2 The British
Cardiovascular Intervention Society had also recommended that
PCI should be used instead of coronary artery bypass grafting in
order to reduce inpatient stays.16 This is likely to contribute for
our findings of more marked reductions in coronary artery bypass
Figure 2 Number of cardiac operations and interventions during the COVID-19 pandemic. Graphs show (A) mean per cent (SD) change in the
weekly number and (B) change in the total number of cardiac operations and interventions during the 3 months of lockdown. In (A), changes in rela-
tion to reference period in 2019 were all statistically significant (P < 0.001). AF, atrial fibrillation; AVR, surgical aortic valve replacement; CABG, coro-
nary artery bypass graft; CRT-D, cardiac resynchronization therapy-defibrillation; CRT-P, cardiac resynchronization therapy-pacing; ICD, implantable
cardioverter-defibrillator; MVR, mitral valve replacement; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; TAVI, transcatheter
aortic valve implantation.
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grafting and valve surgery, compared to PCI and transcatheter
aortic valve implantation. The shortage of intensive care beds,
which are required for all patients undergoing cardiac surgery, is a
continuing challenge.
We observed significant reduction in both elective and emergency
hospitalizations during the lockdown period. This is perhaps not
surprising, given the observed reduction in the number of hospitaliza-
tions of patients with MI and HF. This is also consistent generalized
reduction in attendances to hospital observed by others.5–7 Further
studies are needed to determine to what extent the ‘excess deaths’
reported in national figures are due to underprovision of cardiac
operations and procedures.
Figure 3 Number of cardiac operations and interventions during the COVID-19 pandemic according to hospitalization type. Graphs show (A)
mean per cent (SD) change in the weekly number and (B) change in the total number of cardiac operations and interventions during the 3 months of
lockdown, according to hospitalization type (emergency or elective). In (A), changes in relation to the same time period in 2019 were all significant (P
< 0.001), for both emergency and elective hospitalizations. In the case of emergency ablation for conditions other than atrial fibrillation, but weekly
rate was highly variable (median reduction: 7.14%; interquartile range 31.6 to 16.7). AF, atrial fibrillation; AVR, surgical aortic valve replacement;
CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy-defibrillation; CRT-P, cardiac resynchronization therapy-pacing; ICD,
implantable cardioverter-defibrillator; MVR, mitral valve replacement; PCI, percutaneous coronary intervention; PPM, permanent pacemaker; TAVI,
transcatheter aortic valve implantation.






/europace/advance-article/doi/10.1093/europace/euab013/6199220 by guest on 07 April 2021
The operations and procedures described herein are for patients
with conditions that carry a major threat to survival and quality of life.
In this regard, there is a 44% mortality in 1 year for untreated symp-
tomatic severe aortic stenosis17 and a 22% mortality in 1 year for se-
vere untreated mitral stenosis.18 With respect to MI, West et al.19
found that in England, the 30-day all-cause mortality rate for hospitals
performing PCI on >25% of ST-elevation MI patients was almost dou-
ble that of hospitals performing it on more than 75%. The survival
benefits of cardiac device implantation, including pacemakers, cardiac
resynchronization therapy, and implantable cardioverter-defibrillator
therapy have also been clearly established.20 It follows that not
undertaking these operations or procedures or delaying them is likely
to translate into poor patient outcomes.
The fluid nature of the pandemic makes it difficult to predict
the long-term impact of the COVID-19 pandemic on the delivery
of cardiac operations and interventions. Within the time window
of the present study, none of the cardiac operations or interven-
tions returned to ‘baseline’ levels by late July 2020. Whilst the
repercussions from other ‘waves’ are likely to be less acute, a less
acute but more sustained reduction may well exceed the impact
observed during the ‘first wave’, particularly over the winter
months.
Figure 4 Hospitalizations for myocardial infarction and heart failure in England during the COVID-19 pandemic. Graphs show weekly numbers of
hospitalizations. Dashed horizontal lines indicate the mean weekly number of hospitalizations during the reference period in 2019. Mean (95% CI) are
shown above the lines. The black, vertical, dashed line marks the announcement of the national ‘lockdown’, on 23 March 2020. Changes in weekly
rates in relation corresponding weeks during the reference period in 2019 were all statistically significant (P < 0.001).
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Limitations
This study has several limitations. Importantly, it is based on an ad-
ministrative rather than on a clinical database. Whilst this approach is
rich in numbers, it is scant in clinical detail. Nevertheless, an adminis-
trative database is more apt to capture hospitalization episodes more
reliably than a clinical database. We cannot reliably model what may
happen in the long term, as the pandemic may involve additional
‘waves’. As this dataset only captures in-hospital activity, we cannot
quantify out of hospital activity, such as out of hospital cardiac arrests
and events which did not necessarily lead to a hospitalization.
Conclusions
The ‘first wave’ of the COVID-19 pandemic has led to a substantial
reduction in the number of cardiac operations and interventions un-
dertaken in England. These findings, which are consistent with studies
from other countries, pose a challenge to the provision of healthcare
to patients with cardiac conditions, during and after the pandemic.
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Supplementary material is available at Europace online.
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